According to analysts from Credit Suisse, the prices of brand name drugs are significantly increasing, due to fast-approaching patent expiration dates and the desire to capitalize on recent approvals. Of the 140 drugs the company tracks, 43 have had a price increase in the second quarter of 2015, setting a record for the most number of products to have a jump in any second quarter.
Read the original story from Barron’s.
